Literature DB >> 22379065

Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients.

María Ángeles Clari1, Beatriz Muñoz-Cobo, Carlos Solano, Isabel Benet, Elisa Costa, María José Remigia, Dayana Bravo, Paula Amat, David Navarro.   

Abstract

The performance of the QuantiFERON-cytomegalovirus (CMV) assay was compared to that of a flow cytometry intracellular cytokine staining (ICS) method for the detection of CMV-specific gamma interferon (IFN-γ)-producing CD8(+) T-cell responses in allogeneic stem cell transplant (allo-SCT) recipients and for estimations of their magnitude and functionality. A total of 90 whole-blood specimens from 23 allo-SCT recipients was analyzed by both methods. Overall, the percentage of specimens that yielded concordant results by both methods was 68.8% (κ = 0.691; 95% confidence interval [CI], 0.548 to 0.835), and the sensitivity of the QuantiFERON-CMV assay for the detection of positive IFN-γ T-cell responses (>0.2 IU/ml), taking the ICS method as the reference, was 76.3%. The magnitude of IFN-γ-producing CD8(+) T-cell responses to CMV-specific peptides measured with the QuantiFERON-CMV assay correlated significantly (σ = 0.695; P = <0.001) with that of the total IFN-γ-producing CD8(+) T cells and dual-functional (IFN-γ/tumor necrosis factor alpha [TNF-α] [σ = 0.652; P = <0.001] and IFN-γ/CD107a [σ = 0.690; P = <0.001]) and trifunctional (IFN-γ/TNF-α/CD107a [σ = 0.679; P = >0.001]) CMV-specific CD8(+) T-cell responses, as quantitated by ICS. In summary, the data indicated that the QuantiFERON-CMV assay is less sensitive than the ICS method for the detection of CMV-specific IFN-γ-producing CD8(+) T-cell responses in the allo-SCT setting. Nevertheless, it allowed the estimation of the total and polyfunctional CMV-specific IFN-γ-producing CD8(+) T-cell responses in specimens that tested positive by both methods.

Entities:  

Mesh:

Year:  2012        PMID: 22379065      PMCID: PMC3346332          DOI: 10.1128/CVI.05633-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  18 in total

1.  Functional profile of cytomegalovirus (CMV)-specific CD8+ T cells and kinetics of NKG2C+ NK cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients.

Authors:  Beatriz Muñoz-Cobo; Carlos Solano; Isabel Benet; Elisa Costa; María José Remigia; Rafael de la Cámara; José Nieto; Javier López; Paula Amat; Ana Garcia-Noblejas; Dayana Bravo; María Ángeles Clari; David Navarro
Journal:  J Med Virol       Date:  2012-02       Impact factor: 2.327

Review 2.  Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients.

Authors:  Per Ljungman
Journal:  J Clin Virol       Date:  2006-01-18       Impact factor: 3.168

3.  Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients.

Authors:  Simon F Lacey; Corinna La Rosa; Wendy Zhou; Madeva C Sharma; Joy Martinez; Aparna Krishnan; Ghislaine Gallez-Hawkins; Lia Thao; Jeff Longmate; Ricardo Spielberger; Stephen J Forman; Ajit Limaye; John A Zaia; Don J Diamond
Journal:  J Infect Dis       Date:  2006-10-11       Impact factor: 5.226

4.  Enumeration of cytomegalovirus-specific interferongamma CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection.

Authors:  Carlos Solano; Isana Benet; María A Clari; José Nieto; Rafael de la Cámara; Javier López; Juan C Hernández-Boluda; María J Remigia; Isidro Jarque; María L Calabuig; Ana Garcia-Noblejas; Juan Alberola; Amparo Tamarit; Concepción Gimeno; David Navarro
Journal:  Haematologica       Date:  2008-07-04       Impact factor: 9.941

5.  Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients.

Authors:  Concepción Gimeno; Carlos Solano; José C Latorre; Juan C Hernández-Boluda; María A Clari; María J Remigia; Santiago Furió; Marisa Calabuig; Nuria Tormo; David Navarro
Journal:  J Clin Microbiol       Date:  2008-08-27       Impact factor: 5.948

6.  Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity.

Authors:  G P Westall; N A Mifsud; T Kotsimbos
Journal:  Am J Transplant       Date:  2008-06-28       Impact factor: 8.086

7.  Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection.

Authors:  Nuria Tormo; Carlos Solano; Isabel Benet; José Nieto; Rafael de la Cámara; Ana Garcia-Noblejas; María Angeles Clari; Marifina Chilet; Javier López; Juan Carlos Hernández-Boluda; María José Remigia; David Navarro
Journal:  J Med Virol       Date:  2010-07       Impact factor: 2.327

8.  Polyfunctional cytomegalovirus-specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation.

Authors:  G Nebbia; F M Mattes; C Smith; E Hainsworth; J Kopycinski; A Burroughs; P D Griffiths; P Klenerman; V C Emery
Journal:  Am J Transplant       Date:  2008-10-06       Impact factor: 8.086

9.  Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT.

Authors:  G Avetisyan; J Aschan; H Hägglund; O Ringdén; P Ljungman
Journal:  Bone Marrow Transplant       Date:  2007-08-27       Impact factor: 5.483

10.  Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV.

Authors:  S Walker; C Fazou; T Crough; R Holdsworth; P Kiely; M Veale; S Bell; A Gailbraith; K McNeil; S Jones; R Khanna
Journal:  Transpl Infect Dis       Date:  2007-06       Impact factor: 2.228

View more
  18 in total

Review 1.  The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Miriam Ciáurriz; Amaya Zabalza; Lorea Beloki; Cristina Mansilla; Estela Pérez-Valderrama; Mercedes Lachén; Eva Bandrés; Eduardo Olavarría; Natalia Ramírez
Journal:  Cell Mol Life Sci       Date:  2015-07-15       Impact factor: 9.261

2.  Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.

Authors:  Roy F Chemaly; Lynn El Haddad; Drew J Winston; Scott D Rowley; Kathleen M Mulane; Pranatharthi Chandrasekar; Robin K Avery; Parameswaran Hari; Karl S Peggs; Deepali Kumar; Rajneesh Nath; Per Ljungman; Sherif B Mossad; Sanjeet S Dadwal; Ted Blanchard; Dimpy P Shah; Ying Jiang; Ella Ariza-Heredia
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

3.  The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.

Authors:  Lynn El Haddad; Ella Ariza-Heredia; Dimpy P Shah; Ying Jiang; Ted Blanchard; Shashank S Ghantoji; Firas El Chaer; Danielle El-Haddad; Amrita Prayag; Lior Nesher; Katy Rezvani; Elizabeth Shpall; Roy F Chemaly
Journal:  J Infect Dis       Date:  2019-02-23       Impact factor: 5.226

4.  Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment.

Authors:  Elena Beam; Raymund R Razonable
Journal:  Curr Infect Dis Rep       Date:  2012-12       Impact factor: 3.725

Review 5.  CMV-specific immune reconstitution following allogeneic stem cell transplantation.

Authors:  Emily Blyth; Barbara Withers; Leighton Clancy; David Gottlieb
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

6.  Clinical Experience with Immune Monitoring for Cytomegalovirus in Solid-Organ Transplant Recipients.

Authors:  Oriol Manuel
Journal:  Curr Infect Dis Rep       Date:  2013-09-29       Impact factor: 3.725

Review 7.  In-depth summary over cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation recipients.

Authors:  Samira Karami; Elham Roshandel; Haniyeh Ghaffari Nazari; Abbas Hajifathali; Farzaneh Tavakoli; Sayeh Parkhideh
Journal:  Virusdisease       Date:  2021-07-28

8.  Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.

Authors:  Davide Abate; Alda Saldan; Carlo Mengoli; Marta Fiscon; Cristina Silvestre; Loredana Fallico; Marta Peracchi; Lucrezia Furian; Riccardo Cusinato; Luciana Bonfante; Barbara Rossi; Francesco Marchini; Dino Sgarabotto; Paolo Rigotti; Giorgio Palù
Journal:  J Clin Microbiol       Date:  2013-05-15       Impact factor: 5.948

9.  Association of human cytomegalovirus DNAaemia and specific granzyme B responses in lung transplant recipients.

Authors:  L Weseslindtner; H Kerschner; D Steinacher; M Kundi; P Jaksch; B Simon; L Hatos-Agyi; A Scheed; W Klepetko; E Puchhammer-Stöckl
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

10.  Association of CMV-Specific T Cell-Mediated Immunity with CMV DNAemia and Development of CMV Disease in HIV-1-Infected Individuals.

Authors:  Maximilian C Aichelburg; Lukas Weseslindtner; Mattias Mandorfer; Robert Strassl; Armin Rieger; Thomas Reiberger; Elisabeth Puchhammer-Stöckl; Katharina Grabmeier-Pfistershammer
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.